|
1
|
Ostrom QT, Price M, Neff C, Cioffi G,
Waite KA, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the united states in 2016-2020. Neuro Oncol.
25:IV1–IV99. 2023.PubMed/NCBI
|
|
2
|
Bertolini F, Spallanzani A, Fontana A,
Depenni R and Luppi G: Brain metastases: An overview. CNS Oncol.
4:37–46. 2015.PubMed/NCBI
|
|
3
|
Englot DJ, Magill ST, Han SJ, Chang EF,
Berger MS and McDermott MW: Seizures in supratentorial meningioma:
A systematic review and meta-analysis. J Neurosurg.
124:15522015.PubMed/NCBI
|
|
4
|
Englot DJ, Chang EF and Vecht CJ: Epilepsy
and brain tumors. Handb Clin Neurol. 134:267–285. 2016.PubMed/NCBI
|
|
5
|
Easwaran TP, Lancki N, Henriquez M,
Vortmeyer AO, Barbaro NM, Scholtens DM, Ahmed AU and Dey M:
Molecular classification of gliomas is associated with seizure
control: A retrospective analysis. Neuromolecular. 23:315–326.
2021.
|
|
6
|
Chen H, Judkins J, Thomas C, Wu M, Khoury
L, Benjamin CG, Pacione D, Golfinos JG, Kumthekar P and Ghamsari F:
Mutant IDH1 and seizures in patients with glioma. Neurology.
88:1805–1813. 2017.PubMed/NCBI
|
|
7
|
Seidel S, Wehner T, Miller D, Wellmer J,
Schlegel U and Grönheit W: Brain tumor related epilepsy:
Pathophysiological approaches and rational management of
antiseizure medication. Neurol Res Pract. 4:452022.PubMed/NCBI
|
|
8
|
Soltani Khaboushan A, Yazdanpanah N and
Rezaei N: Neuroinflammation and proinflammatory cytokines in
epileptogenesis. Mol Neurobiol. 59:1724–1743. 2022.PubMed/NCBI
|
|
9
|
Rana A and Musto AE: The role of
inflammation in the development of epilepsy. J Neuroinflammation.
15:1442018.PubMed/NCBI
|
|
10
|
Zhu X, Dong J, Han B, Huang R, Zhang A,
Xia Z, Chang H, Chao J and Yao H: Neuronal nitric oxide synthase
contributes to PTZ kindling epilepsy-induced hippocampal
endoplasmic reticulum stress and oxidative damage. Front Cell
Neurosci. 11:3772017.PubMed/NCBI
|
|
11
|
Xiao Z, Peng J, Wu L, Arafat A and Yin F:
The effect of IL-1β on synaptophysin expression and
electrophysiology of hippocampal neurons through the PI3K/Akt/mTOR
signaling pathway in a rat model of mesial temporal lobe epilepsy.
Neurol Res. 39:640–648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roseti C, van Vliet EA, Cifelli P, Ruffolo
G, Baayen JC, Di Castro MA, Bertollini C, Limatola C, Aronica E,
Vezzani A and Palma E: GABAA currents are decreased by IL-1β in
epileptogenic tissue of patients with temporal lobe epilepsy:
Implications for ictogenesis. Neurobiol Dis. 82:311–320. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stellwagen D and Malenka RC: Synaptic
scaling mediated by glial TNF-α. Nature. 440:1054–1059. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balosso S, Ravizza T, Perego C, Peschon J,
Campbell IL, De Simoni MG and Vezzani A: Tumor necrosis factor-α
inhibits seizures in mice via p75 receptors. Ann Neurol.
57:804–812. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galic MA, Riazi K and Pittman QJ:
Cytokines and brain excitability. Front Neuroendocrinol.
33:116–125. 2011. View Article : Google Scholar
|
|
16
|
Takeuchi H, Jin S, Wang J, Zhang G,
Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T and Suzumura A: Tumor
necrosis factor-α induces neurotoxicity via glutamate release from
hemichannels of activated microglia in an autocrine manner. J Biol
Chem. 281:21362–21368. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuhas Y, Weizman A and Ashkenazi S:
Bidirectional concentration-dependent effects of tumor necrosis
factor alpha in Shigella dysenteriae-related seizures. Infect
Immun. 71:2288–2291. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grell M, Wajant H, Zimmermann G and
Scheurich P: The type 1 receptor (CD120a) is the high-affinity
receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA.
95:570–575. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stellwagen D, Beattie EC, Seo JY and
Malenka RC: Differential regulation of AMPA receptor and GABA
receptor trafficking by tumor necrosis factor-α. J Neurosci.
25:3219–3228. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu CY, He XY, Li XF, Zhang X, Huang ZW, Li
J, Chen M and Duan CZ: Nefiracetam attenuates Pro-inflammatory
cytokines and GABA transporter in specific brain regions of rats
with Post-ischemic seizures. Cell Physiol Biochem. 37:2023–2031.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su J, Yin J, Qin W, Sha S, Xu J and Jiang
C: Role for Pro-inflammatory cytokines in regulating expression of
GABA transporter type 1 and 3 in specific brain regions of kainic
Acid-induced status epilepticus. Neurochem Res. 40:621–627.
2015.PubMed/NCBI
|
|
22
|
Iori V, Maroso M, Rizzi M, Iyer AM,
Vertemara R, Carli M, Agresti A, Antonelli A, Bianchi ME, Aronica
E, et al: Receptor for advanced glycation endproducts is
upregulated in temporal lobe epilepsy and contributes to
experimental seizures. Neurobiol Dis. 58:102–114. 2013.PubMed/NCBI
|
|
23
|
Xie J, Méndez JD, Méndez-Valenzuela V and
Aguilar-Hernández MM: Cellular signalling of the receptor for
advanced glycation end products (RAGE). Cell Signal. 25:2185–2197.
2013.PubMed/NCBI
|
|
24
|
Chang ZL: Important aspects of Toll-like
receptors, ligands and their signaling pathways. Inflamm Res.
59:791–808. 2010.PubMed/NCBI
|
|
25
|
Balosso S, Liu J, Bianchi ME and Vezzani
A: Disulfide-containing high mobility group Box-1 promotes
N-Methyl-d-Aspartate receptor function and excitotoxicity by
activating Toll-like receptor 4-Dependent signaling in hippocampal
neurons. Antioxid Redox Signal. 21:1726–1740. 2014.
|
|
26
|
Festoff BW, Sajja RK, van Dreden P and
Cucullo L: HMGB1 and thrombin mediate the blood-brain barrier
dysfunction acting as biomarkers of neuroinflammation and
progression to neurodegeneration in Alzheimer's disease. J
Neuroinflammation. 13:1942016.PubMed/NCBI
|
|
27
|
Maroso M, Balosso S, Ravizza T, Liu J,
Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, Manfredi
AA, et al: Toll-like receptor 4 and high-mobility group box-1 are
involved in ictogenesis and can be targeted to reduce seizures. Nat
Med. 16:413–419. 2010.PubMed/NCBI
|
|
28
|
Ulusoy C, Vanlı-Yavuz EN, Şanlı E,
Timirci-Kahraman Ö, Yılmaz V, Bebek N, Küçükali Cİ, Baykan B and
Tüzün E: Peripheral blood expression levels of inflammasome complex
components in two different focal epilepsy syndromes. J
Neuroimmunol. 347:5773432020.PubMed/NCBI
|
|
29
|
Vezzani A, Balosso S and Ravizza T:
Neuroinflammatory pathways as treatment targets and biomarkers in
epilepsy. Nat Rev Neurol. 15:459–472. 2019.PubMed/NCBI
|
|
30
|
Kigerl KA, de Rivero Vaccari JP, Dietrich
WD, Popovich PG and Keane RW: Pattern recognition receptors and
central nervous system repair. Exp Neurol. 258:5–16.
2014.PubMed/NCBI
|
|
31
|
Vezzani A and Baram TZ: New Roles for
interleukin-1 beta in the mechanisms of epilepsy. Epilepsy Curr.
7:45–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JY, Kanai Y, Chairoungdua A, Cha SH,
Matsuo H, Kim DK, Inatomi J, Sawa H, Ida Y and Endou H: Human
cystine/glutamate transporter: cDNA cloning and upregulation by
oxidative stress in glioma cells. Biochim Biophys Acta.
1512:335–344. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Groot J and Sontheimer H: Glutamate and
the biology of gliomas. Glia. 59:1181–1189. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Savaskan NE, Fan Z, Broggini T, Buchfelder
M and Eyüpoglu IY: Neurodegeneration in the brain tumor
microenvironment: Glutamate in the limelight. Curr Neuropharmacol.
13:258–265. 2015. View Article : Google Scholar :
|
|
35
|
Venkatesh HS, Morishita W, Geraghty AC,
Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami
A, Ni L, et al: Electrical and synaptic integration of glioma into
neural circuits. Nature. 573:539–545. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Groot M, Reijneveld JC, Aronica E and
Heimans JJ: Epilepsy in patients with a brain tumour: Focal
epilepsy requires focused treatment. Brain. 135:1002–1016. 2012.
View Article : Google Scholar
|
|
37
|
Kim JW and Dang CV: Cancer's molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mortazavi A, Fayed I, Bachani M, Dowdy T,
Jahanipour J, Khan A, Owotade J, Walbridge S, Inati SK, Steiner J,
et al: IDH-mutated gliomas promote epileptogenesis through
d-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro Oncol.
24:1423–1435. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Szopa W, Burley TA, Kramer-Marek G and
Kaspera W: Diagnostic and therapeutic biomarkers in glioblastoma:
Current status and future perspectives. Biomed Res Int.
2017:80135752017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Dube C, Gibert M Jr, Cruickshanks
N, Wang B, Coughlan M, Yang Y, Setiady I, Deveau C, Saoud K, et al:
The p53 pathway in glioblastoma. Cancers (Basel). 10:2972018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Smith JS, Tachibana I, Passe SM, Huntley
BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW,
James CD, et al: PTEN mutation, EGFR Amplification, and outcome in
patients with anaplastic astrocytoma and glioblastoma multiforme. J
Natl Cancer Inst. 93:1246–1256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hu S, Kao HY, Yang T and Wang Y: Early and
Bi-hemispheric seizure onset in a rat glioblastoma Multiforme
model. Neurosci Lett. 766:1363512022. View Article : Google Scholar
|
|
44
|
Venkatesan S, Lamfers MLM, Dirven CMF and
Leenstra S: Genetic biomarkers of drug response for small-molecule
therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in
glioblastoma. CNS Oncol. 5:77–790. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Williams MR, De-Spenza T, Li M, Gulledge
AT and Luikart BW: Hyperactivity of newborn pten Knock-out neurons
results from increased excitatory synaptic drive. J Neurosci.
35:943–953. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yonan JM, Chen KD, Baram TZ and Steward O:
PTEN deletion in the adult dentate gyrus induces epilepsy.
Neurobiol Dis. 203:1067362024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hills KE, Kostarelos K and Wykes RC:
Converging mechanisms of epileptogenesis and their insight in
glioblastoma. Front Mol Neurosci. 15:9031152022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sabetghadam A, Wu C, Liu J, Zhang L and
Reid AY: Increased epileptogenicity in a mouse model of
neurofibromatosis type 1. Exp Neurol. 331:1133732020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Engel T, Murphy BM, Schindler CK and
Henshall DC: Elevated p53 and lower MDM2 expression in hippocampus
from patients with intractable temporal lobe epilepsy. Epilepsy
Res. 77:151–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Morrison RS, Wenzel HJ, Kinoshita Y,
Robbins CA, Donehower LA and Schwartzkroin PA: Loss of the p53
tumor suppressor gene protects neurons from kainate-induced cell
death. J Neurosci. 16:1337–1345. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Engel T, Murphy BM, Hatazaki S,
Jimenez-Mateos EM, Concannon CG, Woods I, Prehn JH and Henshall DC:
Reduced hippocampal damage and epileptic seizures after status
epilepticus in mice lacking proapoptotic Puma. FASEB J. 24:853–861.
2010. View Article : Google Scholar
|
|
52
|
Burla R, La Torre M, Zanetti G,
Bastianelli A, Merigliano C, Del Giudice S, Vercelli A, Di Cunto F,
Boido M, Vernì F and Saggio I: P53-sensitive epileptic behavior and
inflammation in Ft1 hypomorphic mice. Front Genet. 9:5812018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Culmsee C, Zhu X, Yu QS, Chan SL,
Camandola S, Guo Z, Greig NH and Mattson MP: A synthetic inhibitor
of p53 protects neurons against death induced by ischemic and
excitotoxic insults, and amyloid β-peptide. J Neurochem.
77:220–228. 2001.PubMed/NCBI
|
|
54
|
Djebali M, Lerner-Natoli M, Pascale M,
Baille V, Bockaert J and Rondouin G: Molecular events involved in
neuronal death induced in the mouse hippocampus by in-vivo
injection of kainic acid. Brain Res Mol Brain Res. 93:190–198.
2001. View Article : Google Scholar
|
|
55
|
Butt AM and Kalsi A: Inwardly rectifying
potassium channels (Kir) in central nervous system glia: A special
role for Kir4.1 in glial functions. J Cell Mol Med. 10:33–44. 2007.
View Article : Google Scholar
|
|
56
|
Nadella RK, Chellappa A, Subramaniam AG,
More RP, Shetty S, Prakash S, Ratna N, Vandana VP, Purushottam M,
Saini J, et al: Identification and functional characterization of
two novel mutations in KCNJ10 and PI4KB in SeSAME syndrome without
electrolyte imbalance. Hum Genomics. 13:532019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Reichold M, Zdebik AA, Lieberer E,
Rapedius M, Schmidt K, Bandulik S, Sterner C, Tegtmeier I, Penton
D, Baukrowitz T, et al: KCNJ10 gene mutations causing EAST syndrome
(epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt
channel function. Proc Natl Acad Sci USA. 107:14490–14495. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Curry RN, Aiba I, Meyer J, Lozzi B, Ko Y,
McDonald MF, Rosenbaum A, Cervantes A, Huang-Hobbs E, Cocito C, et
al: Glioma epileptiform activity and progression are driven by
IGSF3-mediated potassium dysregulation. Neuron. 111:682–695.e9.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
de Curtis M, Uva L, Gnatkovsky V and
Librizzi L: Potassium dynamics and seizures: Why is potassium
ictogenic? Epilepsy Res. 143:50–59. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Audrey C, Lim KS, Ahmad Zaki R, Narayanan
V, Fong SL and Tan CT: From location to manifestation: A systematic
review and meta-analysis of seizure prevalence in different brain
tumor sites. Brain Disord. 14:1001462024. View Article : Google Scholar
|
|
61
|
Lee JW, Wen PY, Hurwitz S, Black P, Kesari
S, Drappatz J, Golby AJ, Wells WM III, Warfield SK, Kikinis R and
Bromfield EB: Morphological characteristics of brain tumors causing
seizures. Arch Neurol. 67:336–342. 2010.PubMed/NCBI
|
|
62
|
Le VT, Nguyen AM, Pham TA and Nguyen PL:
Tumor-related epilepsy and post-surgical outcomes: Tertiary
hospital experience in Vietnam. Sci Rep. 13:108592023.PubMed/NCBI
|
|
63
|
Elbadry Ahmed R, Tang H, Asemota A, Huang
L, Boling W and Bannout F: Meningioma related
Epilepsy-Pathophysiology, Pre/postoperative seizures predicators
and treatment. Front Oncol. 12:9059762022.
|
|
64
|
Harward SC, Rolston JD and Englot DJ:
Seizures in meningioma. Handb Clin Neurol. 170:187–200.
2020.PubMed/NCBI
|
|
65
|
Asano K, Hasegawa S, Matsuzaka M and
Ohkuma H: Brain tumor-related epilepsy and risk factors for
metastatic brain tumors: Analysis of 601 consecutive cases
providing real-world data. J Neurosurg. 136:76–87. 2021.PubMed/NCBI
|
|
66
|
Sankey EW, Tsvankin V, Grabowski MM, Nayar
G, Batich KA, Risman A, Champion CD, Salama AKS, Goodwin CR and
Fecci PE: Operative and peri-operative considerations in the
management of brain metastasis. Cancer Med. 8:6809–6831.
2019.PubMed/NCBI
|
|
67
|
Rudà R, Mo F and Pellerino A: Epilepsy in
brain metastasis: An emerging entity. Curr Treat Options Neurol.
22:62020.PubMed/NCBI
|
|
68
|
Garcia JH, Morshed RA, Chung J, Millares
Chavez MA, Sudhakar V, Saggi S, Avalos LN, Gallagher A, Young JS,
Daras M, et al: Factors associated with preoperative and
postoperative seizures in patients undergoing resection of brain
metastases. J Neurosurg. 138:19–26. 2023.
|
|
69
|
Wolpert F, Lareida A, Terziev R,
Grossenbacher B, Neidert MC, Roth P, Poryazova R, Imbach LL, Le
Rhun E, Weller M, et al: Risk factors for the development of
epilepsy in patients with brain metastases. Neuro Oncol.
22:718–728. 2020.
|
|
70
|
Urban H, Willems LM, Ronellenfitsch MW,
Rosenow F, Steinbach JP and Strzelczyk A: Increased occurrence of
status epilepticus in patients with brain metastases and checkpoint
inhibition. Oncoimmunology. 9:18515172020.PubMed/NCBI
|
|
71
|
Li L, Li G, Fang S, Zhang K, Huang R, Wang
Y, Zhang C, Li Y, Zhang W, Zhang Z, et al: New-Onset postoperative
seizures in patients with diffuse gliomas: A risk assessment
analysis. Front Neurol. 12:6825352021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mastall M, Wolpert F, Gramatzki D, Imbach
L, Becker D, Schmick A, Hertler C, Roth P, Weller M and Wirsching
HG: Survival of brain tumour patients with epilepsy. Brain.
144:3322–3327. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ge H, Di G, Yan Z, Liu D, Liu Y, Song K,
Yang K, Hu X, Jiang Z, Hu X, et al: Does epilepsy always indicate
worse outcomes? A longitudinal follow-up analysis of 485 glioma
patients. World J Surg Oncol. 20:2972022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Vecht CJ, Kerkhof M and Duran-Pena A:
Seizure prognosis in brain tumors: New insights and Evidence-based
management. Oncologist. 19:751–759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Giraldi L, Hansen JV, Wohlfahrt J,
Fugleholm K, Melbye M and Munch TN: Postoperative de novo epilepsy
after craniotomy: A nationwide register-based cohort study. J
Neurol Neurosurg Psychiatry. 93:436–444. 2022. View Article : Google Scholar
|
|
76
|
Abzalova DI, Sinkin MV, Yakovlev AA,
Prirodov AV and Guekht AB: Risk factors for the development of de
novo generalized tonic-clonic epileptic seizures in patients with
supratentorial meningiomas after neurosurgical treatment. Neurosci
Behav Physiol. 54:404–409. 2024.In Russian. View Article : Google Scholar
|
|
77
|
Englot DJ, Berger MS, Barbaro NM and Chang
EF: Predictors of seizure freedom after resection of supratentorial
low-grade gliomas: A review. J Neurosurg. 115:240–244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Schneider M, Güresir Á, Borger V, Hamed M,
Rácz A, Vatter H, Güresir E and Schuss P: Preoperative
tumor-associated epilepsy in patients with supratentorial
meningioma: Factors influencing seizure outcome after meningioma
surgery. J Neurosurg. 133:1655–1661. 2020. View Article : Google Scholar
|
|
79
|
Jackson C, Choi J, Khalafallah AM, Price
C, Bettegowda C, Lim M, Gallia G, Weingart J, Brem H and Mukherjee
D: A systematic review and meta-analysis of supratotal versus gross
total resection for glioblastoma. J Neurooncol. 148:419–431. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Englot DJ, Han SJ, Berger MS, Barbaro NM
and Chang EF: Extent of surgical resection predicts seizure freedom
in low-grade temporal lobe brain tumors. Neurosurgery. 70:921–927.
2012. View Article : Google Scholar
|
|
81
|
Koekkoek JAF, Kerkhof M, Dirven L, Heimans
JJ, Reijneveld JC and Taphoorn MJB: Seizure outcome after
radiotherapy and chemotherapy in low-grade glioma patients: A
systematic review. Neuro Oncol. 17:924–934. 2015.PubMed/NCBI
|
|
82
|
Rudá R, Magliola U, Bertero L, Trevisan E,
Bosa C, Mantovani C, Ricardi U, Castiglione A, Monagheddu C and
Soffietti R: Seizure control following radiotherapy in patients
with diffuse gliomas: A retrospective study. Neuro Oncol.
15:1739–1749. 2013.PubMed/NCBI
|
|
83
|
Van Den Bent MJ, Afra D, De Witte O, Ben
Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L,
Piérart M, Mirimanoff R, et al: Long-term efficacy of early versus
delayed radiotherapy for low-grade astrocytoma and
oligodendroglioma in adults: The EORTC 22845 randomised trial.
Lancet. 366:985–990. 2005.PubMed/NCBI
|
|
84
|
Brada M, Viviers L, Abson C, Hines F,
Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P
and Westbury C: Phase II study of primary temozolomide chemotherapy
in patients with WHO grade II gliomas. Ann Oncol. 14:1715–1721.
2003.PubMed/NCBI
|
|
85
|
Sherman JH, Moldovan K, Yeoh HK, Starke
RM, Pouratian N, Shaffrey ME and Schiff D: Impact of temozolomide
chemotherapy on seizure frequency in patients with low-grade
gliomas: Clinical article. J Neurosurg. 114:1617–1621.
2011.PubMed/NCBI
|
|
86
|
Rades D, Witteler J, Trillenberg P,
Olbrich D, Schild SE, Tvilsted S and Kjaer TW: Increasing seizure
activity during radiation treatment for High-grade Gliomas-final
results of a prospective interventional study. In Vivo.
36:2308–2313. 2022.PubMed/NCBI
|
|
87
|
Wu A, Jin MC, Meola A, Wong HN and Chang
SD: Efficacy and toxicity of particle radiotherapy in WHO grade II
and grade III meningiomas: A systematic review. Neurosurg Focus.
46:E122019.PubMed/NCBI
|
|
88
|
Grewal J, Grewal HK and Forman AD:
Seizures and epilepsy in cancer: Etiologies, Evaluation, and
Management. Curr Oncol Rep. 10:63–71. 2008.PubMed/NCBI
|
|
89
|
Smart DD: Radiation toxicity in the
central nervous system: Mechanisms and strategies for injury
reduction. Semin Radiat Oncol. 27:332–339. 2017.PubMed/NCBI
|
|
90
|
Walbert T, Harrison RA, Schiff D, Avila
EK, Chen M, Kandula P, Lee JW, Le Rhun E, Stevens GHJ, Vogelbaum
MA, et al: SNO and EANO practice guideline update: Anticonvulsant
prophylaxis in patients with newly diagnosed brain tumors. Neuro
Oncol. 23:1835–1844. 2021.PubMed/NCBI
|
|
91
|
Van Der Meer PB, Dirven L, Van Den Bent
MJ, Preusser M, Taphoorn MJB, Rudá R and Koekkoek JAF: Prescription
preferences of antiepileptic drugs in brain tumor patients: An
international survey among EANO members. Neurooncol Pract.
9:105–113. 2022.PubMed/NCBI
|
|
92
|
Dewan MC, Thompson RC, Kalkanis SN, Barker
FG and Hadjipanayis CG: Prophylactic antiepileptic drug
administration following brain tumor resection: Results of a recent
AANS/CNS section on tumors survey. J Neurosurg. 126:1772–1778.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Glauser T, Ben-Menachem E, Bourgeois B,
Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E
and Tomson T; ILAE Subcommission on AED Guidelines: Updated ILAE
evidence review of antiepileptic drug efficacy and effectiveness as
initial monotherapy for epileptic seizures and syndromes.
Epilepsia. 54:551–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Maschio M, Dinapoli L, Sperati F, Pace A,
Fabi A, Vidiri A and Muti P: Levetiracetam monotherapy in patients
with brain tumor-related epilepsy: Seizure control, safety, and
quality of life. J Neurooncol. 104:205–214. 2011. View Article : Google Scholar
|
|
95
|
Bähr O, Hermisson M, Rona S, Rieger J,
Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller
M and Steinbach JP: Intravenous and oral levetiracetam in patients
with a suspected primary brain tumor and symptomatic seizures
undergoing neurosurgery: The HELLO trial. Acta Neurochir (Wien).
154:229–235. 2012. View Article : Google Scholar
|
|
96
|
LaPenna P and Tormoehlen LM: The
pharmacology and toxicology of Third-generation anticonvulsant
drugs. J Med Toxicol. 13:329–342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Jo J, Nevel K, Sutyla R, Smolkin M, Lopes
MB and Schiff D: Predictors of early, recurrent, and intractable
seizures in low-grade glioma. Neurooncol Pract. 8:40–47. 2020.
|
|
98
|
Singh SP, Agarwal S and Faulkner M:
Refractory status epilepticus. Ann Indian Acad Neurol. 17(Suppl 1):
S32–S36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Van Breemen MSM, Rijsman RM, Taphoorn MJB,
Walchenbach R, Zwinkels H and Vecht CJ: Efficacy of anti-epileptic
drugs in patients with gliomas and seizures. J Neurol.
256:1519–1526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Yadav J, Singh P, Dabla S and Gupta R:
Psychiatric comorbidity and quality of life in patients with
epilepsy on anti-epileptic monotherapy and polytherapy. Tzu Chi Med
J. 34:226–231. 2021. View Article : Google Scholar
|
|
101
|
Khalid B, Waqar Z, Khan S, Ali I, Afzal N,
Irfan A, Malik W, Muhammad Adil M, Saddiqa A, Khalil M and Munawar
Z: Psychiatric implications of anti-seizure medications in
epileptic population. BMC Neurol. 24:1662024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Besag FMC, Vasey MJ and Sen A: Current
evidence for adjunct pyridoxine (vitamin B6) for the treatment of
behavioral adverse effects associated with levetiracetam: A
systematic review. Epilepsy Behav. 140:1090652023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Bourg V, Lebrun C, Chichmanian RM, Thomas
P and Frenay M: Nitroso-urea-cisplatin-based chemotherapy
associated with valproate: Increase of haematologic toxicity. Ann
Oncol. 12:217–220. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Simó M, Velasco R, Graus F, Verger E, Gil
M, Pineda E, Blasco J and Bruna J: Impact of antiepileptic drugs on
thrombocytopenia in glioblastoma patients treated with standard
chemoradiotherapy. J Neurooncol. 108:451–458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kerkhof M, Dielemans JCM, Van Breemen MS,
Zwinkels H, Walchenbach R, Taphoorn MJ and Vecht CJ: Effect of
valproic acid on seizure control and on survival in patients with
glioblastoma multiforme. Neuro Oncol. 15:961–967. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Sánchez-Villalobos JM, Aledo-Serrano Á,
Villegas-Martínez I, Shaikh MF and Alcaraz M: Epilepsy treatment in
neuro-oncology: A rationale for drug choice in common clinical
scenarios. Front Pharmacol. 13:9912442022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mo F, Meletti S, Belcastro V, Quadri S,
Napolitano M, Bello L, Dainese F, Scarpelli M, Florindo I, Mascia
A, et al: Lacosamide in monotherapy in BTRE (brain tumor-related
epilepsy): Results from an Italian multicenter retrospective study.
J Neurooncol. 157:551–559. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Villanueva V, Saiz-Diaz R, Toledo M, Piera
A, Mauri JA, Rodriguez-Uranga JJ, López-González FJ, Gómez-Ibáñez
A, Garcés M, González de la Aleja J, et al: NEOPLASM study:
Real-life use of lacosamide in patients with brain tumor-related
epilepsy. Epilepsy Behav. 65:25–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
van Opijnen MP, van der Meer PB, Dirven L,
Fiocco M, Kouwenhoven MCM, van den Bent MJ, Taphoorn MJB and
Koekkoek JAF: The effectiveness of antiepileptic drug treatment in
glioma patients: Lamotrigine versus lacosamide. J Neurooncol.
154:73–81. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wilding J, Van Gaal L, Rissanen A,
Vercruysse F and Fitchet M: A randomized double-blind
placebo-controlled study of the long-term efficacy and safety of
topiramate in the treatment of obese subjects. Int J Obes Relat
Metab Disord. 28:1399–1410. 2004.2004. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu YT, Chen GT, Huang YC, Ho JT, Lee CC,
Tsai CC and Chang CN: Effectiveness of dose-escalated topiramate
monotherapy and add-on therapy in neurosurgery-related epilepsy: A
prospective study. Medicine (Baltimore). 99:e237712020.PubMed/NCBI
|
|
112
|
Maschio M, Dinapoli L, Zarabla A,
Maialetti A, Giannarelli D, Fabi A, Vidiri A and Cantelmi T:
Zonisamide in brain tumor-related epilepsy: An observational pilot
study. Clin Neuropharmacol. 40:113–119. 2017.PubMed/NCBI
|
|
113
|
De A, Rajagopalan M, Sarda A, Das S and
Biswas P: Drug reaction with eosinophilia and systemic symptoms: An
update and review of recent literature. Indian J Dermatol.
63:30–40. 2018.PubMed/NCBI
|
|
114
|
Patocka J, Wu Q, Nepovimova E and Kuca K:
Phenytoin-An anti-seizure drug: Overview of its chemistry,
pharmacology and toxicology. Food Chem Toxicol. 142:1113932020.
|
|
115
|
Mauro AM, Bomprezzi C, Morresi S,
Provinciali L, Formica F, Iacoangeli M and Scerrati M: Prevention
of early postoperative seizures in patients with primary brain
tumors: Preliminary experience with oxcarbazepine. J Neurooncol.
81:279–285. 2007.
|
|
116
|
Maschio M, Dinapoli L, Sperati F, Fabi A,
Pace A, Vidiri A and Muti P: Oxcarbazepine monotherapy in patients
with brain tumor-related epilepsy: Open-label pilot study for
assessing the efficacy, tolerability and impact on quality of life.
J Neurooncol. 106:651–656. 2012.
|
|
117
|
Zoccarato M, Basile AM, Padovan M, Caccese
M, Zagonel V and Lombardi G: Eslicarbazepine in patients with brain
tumor-related epilepsy: A single-center experience. Int J Neurosci.
131:879–884. 2021.
|
|
118
|
Hino U, Tamura R, Kosugi K, Ezaki T,
Karatsu K, Yamamoto K, Tomioka A and Toda M: Optimizing perampanel
monotherapy for surgically resected brain tumors. Mol Clin Oncol.
20:422024.PubMed/NCBI
|
|
119
|
Perry JR and Sawka C: Add-on gabapentin
for refractory seizures in patients with brain tumours. Can J
Neurol Sci. 23:128–131. 1996.PubMed/NCBI
|
|
120
|
Brahmbhatt N, Stupp R, Bushara O, Bachman
E, Schuele SU and Templer JW: Efficacy of clobazam as add-on
therapy in brain tumor-related epilepsy. J Neurooncol. 151:287–293.
2021.PubMed/NCBI
|
|
121
|
Striano S, Striano P, Boccella P, Nocerino
C and Bilo L: Tiagabine in glial tumors. Epilepsy Res. 49:81–85.
2002.PubMed/NCBI
|
|
122
|
Maschio M, Maialetti A, Mocellini C,
Domina E, Pauletto G, Costa C, Mascia A, Romoli M and Giannarelli
D: Effect of brivaracetam on efficacy and tolerability in patients
with brain Tumor-related epilepsy: A retrospective multicenter
study. Front Neurol. 11:8132020.PubMed/NCBI
|
|
123
|
Gao L, Lu Q, Wang Z, Yue W, Wang G, Shao
X, Guo Y, Yi Y, Hong Z, Jiang Y, et al: Efficacy and safety of
perampanel as early add-on therapy in Chinese patients with
focal-onset seizures: A multicenter, open-label, single-arm study.
Front Neurol. 14:12360462023.PubMed/NCBI
|
|
124
|
Lavu A, Aboulatta L, Abou-Setta AM, Aloud
B, Askin N, Rabbani R, Shouman W, Zarychanski R and Eltonsy S:
Efficacy and safety of perampanel in epilepsy: A systematic review
and meta-analysis of randomised controlled trials. Seizure.
102:54–60. 2022.PubMed/NCBI
|
|
125
|
Bénit CP and Vecht CJ: Seizures and
cancer: Drug interactions of anticonvulsants with chemotherapeutic
agents, tyrosine kinase inhibitors and glucocorticoids. Neurooncol
Pract. 3:245–260. 2016.PubMed/NCBI
|
|
126
|
Chalk JB, Ridgeway K, Brophy T, Yelland
JDN and Eadie MJ: Phenytoin impairs the bioavailability of
dexamethasone in neurological and neurosurgical patients. J Neurol
Neurosurg Psychiatry. 47:1087–1090. 1984.PubMed/NCBI
|
|
127
|
Ikeda H, Murakami T, Takano M, Usui T and
Kihira K: Pharmacokinetic interaction on valproic acid and
recurrence of epileptic seizures during chemotherapy in an
epileptic patient. Br J Clin Pharmacol. 59:593–597. 2005.PubMed/NCBI
|
|
128
|
Bagnato F and Good J: The use of
antiepileptics in migraine prophylaxis. Headache. 56:603–615.
2016.PubMed/NCBI
|
|
129
|
Linde M, Mulleners WM, Chronicle EP and
Mccrory DC: Antiepileptics other than gabapentin, pregabalin,
topiramate, and valproate for the prophylaxis of episodic migraine
in adults. Cochrane Database Syst Rev. 2013:CD0106082013.PubMed/NCBI
|
|
130
|
Ruiz-Giménez J, Sánchez-Álvarez JC,
Cañadillas-Hidalgo F and Serrano-Castro PJ: Antiepileptic treatment
in patients with epilepsy and other comorbidities. Seizure.
19:375–382. 2010.PubMed/NCBI
|
|
131
|
Patsalos PN and Perucca E: Clinically
important drug interactions in epilepsy: Interactions between
antiepileptic drugs and other drugs. Lancet Neurol. 2:473–481.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Routy JP, Tremblay CL, Angel JB, Trottier
B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N,
et al: Valproic acid in association with highly active
antiretroviral therapy for reducing systemic HIV-1 reservoirs:
Results from a multicentre randomized clinical study. HIV Med.
13:291–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Lehrman G, Hogue IB, Palmer S, Jennings C,
Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW,
et al: Depletion of latent HIV-1 infection in vivo: A
proof-of-concept study. Lancet. 366:5492005. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sagot-Lerolle N, Lamine A, Chaix ML,
Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C,
Delfraissy JF and Lambotte O; ANRS EP39 study: Prolonged valproic
acid treatment does not reduce the size of latent HIV reservoir.
AIDS. 22:1125–1129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Blotière PO, Raguideau F, Weill A, Elefant
E, Perthus I, Goulet V, Rouget F, Zureik M, Coste J and Dray-Spira
R: Risks of 23 specific malformations associated with prenatal
exposure to 10 antiepileptic drugs. Neurology. 93:e167–e180. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Jentink J, Loane MA, Dolk H, Barisic I,
Garne E, Morris JK and de Jong-van den Berg LT; EUROCAT
Antiepileptic Study Working Group: Valproic acid monotherapy in
pregnancy and major congenital malformations. N Engl J Med.
362:2185–2193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Meador KJ, Baker GA, Browning N, Cohen MJ,
Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD,
Pennell PB, et al: Fetal antiepileptic drug exposure and cognitive
outcomes at age 6 years (NEAD study): A prospective observational
study. Lancet Neurol. 12:244–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Christensen J, Grnøborg TK, Srøensen MJ,
Schendel D, Parner ET, Pedersen LH and Vestergaard M: Prenatal
valproate exposure and risk of autism spectrum disorders and
childhood autism. JAMA. 309:1696–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Venkatesh HS, Johung TB, Caretti V, Noll
A, Tang Y, Nagaraja S, Gibson EM, Mount CW, Polepalli J, Mitra SS,
et al: Neuronal activity promotes glioma growth through
Neuroligin-3 secretion. Cell. 161:803–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Venkataramani V, Tanev DI, Strahle C,
Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M,
Ratliff M, Xie R, et al: Glutamatergic synaptic input to glioma
cells drives brain tumour progression. Nature. 573:532–538. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Stepulak A, Sifringer M, Rzeski W,
Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U,
Kaindl AM, Bührer C, et al: NMDA antagonist inhibits the
extracellular signal-regulated kinase pathway and suppresses cancer
growth. Proc Natl Acad Sci USA. 102:15605–15610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Bobustuc GC, Baker CH, Limaye A, Jenkins
WD, Pearl G, Avgeropoulos NG and Konduri SD: Levetiracetam enhances
p53-mediated MGMT inhibition and sensitizes glioblastoma cells to
temozolomide. Neuro Oncol. 12:917–927. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Roh TH, Moon JH, Park HH, Kim EH, Hong CK,
Kim SH, Kang SG and Chang JH: Association between survival and
levetiracetam use in glioblastoma patients treated with
temozolomide chemoradiotherapy. Sci Rep. 10:107832020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Ryu JY, Min KL and Chang MJ: Effect of
anti-epileptic drugs on the survival of patients with glioblastoma
multiforme: A retrospective, single-center study. PLoS One.
14:e02255992019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Chen JS, Clarke R, Haddad AF, Wang EJ,
Lacroix M, Sarkar IN, Zand R, Chen ES and Toms SA: The effect of
levetiracetam treatment on survival in patients with glioblastoma:
A systematic review and meta-analysis. J Neurooncol. 156:257–267.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Happold C, Gorlia T, Chinot O, Gilbert MR,
Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, et al:
Does valproic acid or levetiracetam improve survival in
glioblastoma? A pooled analysis of prospective clinical trials in
newly diagnosed glioblastoma. J Clin Oncol. 34:731–739. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Oberndorfer S, Piribauer M, Marosi C,
Lahrmann H, Hitzenberger P and Grisold W: P450 enzyme inducing and
non-enzyme inducing antiepileptics in glioblastoma patients treated
with standard chemotherapy. J Neurooncol. 72:255–260. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Krauze A, Megan M, Theresa CZ, Peter M,
Shih JH, Tofilon PJ, Rowe L, Gilbert M and Camphausen K: The
addition of Valproic acid to concurrent radiation therapy and
temozolomide improves patient outcome: A Correlative analysis of
RTOG 0525, SEER and a Phase II NCI trial. Cancer Stud Ther.
5:310382020.
|
|
149
|
Weller M, Gorlia T, Cairncross JG, van den
Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR,
Forsyth P, et al: Prolonged survival with valproic acid use in the
EORTC/NCIC temozolomide trial for glioblastoma. Neurology.
77:1156–1164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Michaelis M, Doerr HW and Jr JC: Valproic
acid as Anti-cancer drug. Curr Pharm Des. 13:3378–3393. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG
and Heinzel T: Valproic acid defines a novel class of HDAC
inhibitors inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Salmaggi A, Corno C, Maschio M, Donzelli
S, D'urso A, Perego P and Ciusani E: Synergistic effect of
perampanel and temozolomide in human glioma cell lines. J Pers Med.
11:3902021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Lange F, Weßlau K, Porath K, Hörnschemeyer
MF, Bergner C, Krause BJ, Mullins CS, Linnebacher M, Köhling R and
Kirschstein T: AMPA receptor antagonist perampanel affects
glioblastoma cell growth and glutamate release in vitro. PLoS One.
14:e02116442019. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Lange F, Hartung J, Liebelt C, Boisserée
J, Resch T, Porath K, Hörnschemeyer MF, Reichart G, Sellmann T,
Neubert V, et al: Perampanel Add-on to standard radiochemotherapy
in vivo promotes neuroprotection in a rodent F98 glioma Model.
Front Neurosci. 14:5982662020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Rizzo A, Donzelli S, Girgenti V, Sacconi
A, Vasco C, Salmaggi A, Blandino G, Maschio M and Ciusani E: In
vitro antineoplastic effects of brivaracetam and lacosamide on
human glioma cells. J Exp Clin Cancer Res. 36:762017. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Bang SR, Ambavade SD, Jagdale PG, Adkar
PP, Waghmare AB and Ambavade PD: Lacosamide reduces HDAC levels in
the brain and improves memory: Potential for treatment of
Alzheimer's disease. Pharmacol Biochem Behav. 134:65–69. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Beutler AS, Li S, Nicol R and Walsh MJ:
Carbamazepine is an inhibitor of histone deacetylases. Life Sci.
76:3107–3115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Nelson M, Yang M, Dowle AA, Thomas JR and
Brackenbury WJ: The sodium channel-blocking antiepileptic drug
phenytoin inhibits breast tumour growth and metastasis. Mol Cancer.
14:132015. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Pellegrino M, Rizza P, Nigro A, Ceraldi R,
Ricci E, Perrotta I, Aquila S, Lanzino M, Andò S, Morelli C and
Sisci D: FoxO3a mediates the inhibitory effects of the
antiepileptic drug lamotrigine on breast cancer growth. Mol Cancer
Res. 16:923–934. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Koekkoek JAF, Kerkhof M, Dirven L, Heimans
JJ, Postma TJ, Vos MJ, Bromberg JE, van den Bent MJ, Reijneveld JC
and Taphoorn MJ: Withdrawal of antiepileptic drugs in glioma
patients after long-term seizure freedom: Design of a prospective
observational study. BMC Neurol. 14:1572014. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Das RR, Artsy E, Hurwitz S, Wen PY, Black
P, Golby A, Dworetzky B and Lee JW: Outcomes after discontinuation
of antiepileptic drugs after surgery in patients with low grade
brain tumors and meningiomas. J Neurooncol. 107:565–570. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Tellez-Zenteno JF, Hernandez-Ronquillo L
and Moien-Afshari F: Discontinuation of antiepileptic drugs after
successful surgery: Who and when? Epileptic Disord. 14:363–370.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Berg AT, Langfitt JT, Spencer SS and
Vickrey BG: Stopping antiepileptic drugs after epilepsy surgery: A
survey of U.S. epilepsy center neurologists. Epilepsy Behav.
10:219–222. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Jiang H, Deng G, Liu B, Cheng J, Li Y, Tan
Y, Wang J and Chen Q: Analysis of the short-term outcomes and risk
factors of seizure relapse in patients with gliomas after
antiepileptic drugs withdrawal. J Clin Neurosci. 82:20–25. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Han W, Shi J, Cao J, Dong B and Guan W:
Emerging roles and therapeutic interventions of aerobic glycolysis
in glioma. Onco Targets Ther. 13:6937–6955. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Singh R, Gupta V, Kumar A and Singh K:
2-Deoxy-D-Glucose: A novel pharmacological agent for killing
hypoxic tumor cells, oxygen dependence-lowering in covid-19, and
other pharmacological activities. Adv Pharmacol Pharm Sci.
2023:99933862023.PubMed/NCBI
|
|
167
|
Siclari F, Prior JO and Rossetti AO: Ictal
cerebral positron emission tomography (PET) in focal status
epilepticus. Epilepsy Res. 105:356–361. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Stafstrom CE, Roopra A and Sutula TP:
Seizure suppression via glycolysis inhibition with
2-deoxy-D-glucose (2DG). Epilepsia. 49:97–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Gasior M, Yankura J, Hartman AL, French A
and Rogawski MA: Anticonvulsant and proconvulsant actions of
2-deoxy-d-glucose. Epilepsia. 51:1385–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Minor RK, Smith DL Jr, Sossong AM, Kaushik
S, Poosala S, Spangler EL, Roth GS, Lane M, Allison DB, de Cabo R,
et al: Chronic ingestion of 2-deoxy-D-glucose induces cardiac
vacuolization and increases mortality in rats. Toxicol Appl
Pharmacol. 243:332–339. 2010. View Article : Google Scholar :
|
|
171
|
Tejera D, Kushnirsky M, Gultekin SH, Lu M,
Steelman L and De La Fuente MI: Ivosidenib, an IDH1 inhibitor, in a
patient with recurrent, IDH1-mutant glioblastoma: A case report
from a Phase I study. CNS Oncol. 9:CNS622020. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Vo AH, Ambady P and Spencer D: The IDH1
inhibitor ivosidenib improved seizures in a patient with
drug-resistant epilepsy from IDH1 mutant oligodendroglioma.
Epilepsy Behav Rep. 18:1005262022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Xie Y, Yu N, Chen Y, Zhang K, Ma HY and Di
Q: HMGB1 regulates P-glycoprotein expression in status epilepticus
rat brains via the RAGE/NF-κB signaling pathway. Mol Med Rep.
16:1691–1700. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Chen Y, Huang XJ, Yu N, Xie Y, Zhang K,
Wen F, Liu H and Di Q: HMGB1 Contributes to the Expression of
P-Glycoprotein in mouse epileptic brain through Toll-like receptor
4 and receptor for advanced glycation end products. PLoS One.
10:e01409182015. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Fu L, Liu K, Wake H, Teshigawara K,
Yoshino T, Takahashi H, Mori S and Nishibori M: Therapeutic effects
of anti-HMGB1 monoclonal antibody on pilocarpine-induced status
epilepticus in mice. Sci Rep. 7:11792017. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Ravizza T, Terrone G, Salamone A, Frigerio
F, Balosso S, Antoine DJ and Vezzani A: High Mobility Group Box 1
is a novel pathogenic factor and a mechanistic biomarker for
epilepsy. Brain Behav Immun. 72:14–21. 2018. View Article : Google Scholar
|
|
177
|
Paudel YN, Othman I and Shaikh MF:
Anti-high mobility group Box-1 monoclonal antibody attenuates
Seizure-induced cognitive decline by suppressing neuroinflammation
in an adult zebrafish model. Front Pharmacol. 11:6130092021.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Nishibori M, Mori S and Takahashi HK:
Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and
PNS diseases. J Pharmacol Sci. 140:94–101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Maroso M, Balosso S, Ravizza T, Iori V,
Wright CI, French J and Vezzani A: Interleukin-1β biosynthesis
inhibition reduces acute seizures and drug resistant chronic
epileptic activity in mice. Neurotherapeutics. 8:304–315. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Kaur H, Kumar B and Medhi B: Antiepileptic
drugs in development pipeline: A recent update. eNeurologicalSci.
4:42–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Bertani I, Iori V, Trusel M, Maroso M,
Foray C, Mantovani S, Tonini R, Vezzani A and Chiesa R: Inhibition
of IL-1β signaling normalizes NMDA-Dependent neurotransmission and
reduces seizure susceptibility in a mouse model of
Creutzfeldt-Jakob disease. J Neurosci. 37:10278–10289.
2017.PubMed/NCBI
|
|
182
|
Semple BD, O'Brien TJ, Gimlin K, Wright
DK, Kim SE, Casillas-Espinosa PM, Webster KM, Petrou S and
Noble-Haeusslein LJ: Interleukin-1 receptor in seizure
susceptibility after traumatic injury to the pediatric brain. J
Neurosci. 37:7864–7877. 2017.PubMed/NCBI
|
|
183
|
Dilena R, Mauri E, Aronica E, Bernasconi
P, Bana C, Cappelletti C, Carrabba G, Ferrero S, Giorda R, Guez S,
et al: Therapeutic effect of Anakinra in the relapsing chronic
phase of febrile infection-related epilepsy syndrome. Epilepsia
Open. 4:344–350. 2019.PubMed/NCBI
|
|
184
|
Kenney-Jung DL, Vezzani A, Kahoud RJ,
LaFrance-Corey RG, Ho ML, Muskardin TW, Wirrell EC, Howe CL and
Payne ET: Febrile infection-related epilepsy syndrome treated with
anakinra. Ann Neurol. 80:939–945. 2016.PubMed/NCBI
|
|
185
|
Dilena R, Mauri E, Aronica E, Bernasconi
P, Bana C, Cappelletti C, Carrabba G, Ferrero S, Giorda R, Guez S,
et al: Therapeutic effect of Anakinra in the relapsing chronic
phase of febrile infection-related epilepsy syndrome. Epilepsia
Open. 4:344–350. 2019.PubMed/NCBI
|
|
186
|
Weissberg I, Wood L, Kamintsky L, Vazquez
O, Milikovsky DZ, Alexander A, Oppenheim H, Ardizzone C, Becker A,
Frigerio F, et al: Albumin induces excitatory synaptogenesis
through astrocytic TGF-β/ALK5 signaling in a model of acquired
epilepsy following blood-brain barrier dysfunction. Neurobiol Dis.
78:115–125. 2015.PubMed/NCBI
|
|
187
|
Sanz P and Garcia-Gimeno MA: Reactive glia
inflammatory signaling pathways and epilepsy. Int J Mol Sci.
21:40962020.PubMed/NCBI
|
|
188
|
Benson MJ, Thomas NK, Talwar S, Hodson MP,
Lynch JW, Woodruff TM and Borges K: A novel anticonvulsant
mechanism via inhibition of complement receptor C5ar1 in murine
epilepsy models. Neurobiol Dis. 76:87–97. 2015.PubMed/NCBI
|
|
189
|
Ryther RCC and Wong M: Mammalian target of
rapamycin (mTOR) inhibition: Potential for antiseizure,
antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci
Rep. 12:410–418. 2012.PubMed/NCBI
|
|
190
|
Zeng LH, Xu L, Gutmann DH and Wong M:
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis
complex. Ann Neurol. 63:444–453. 2008.PubMed/NCBI
|
|
191
|
Sunnen CN, Brewster AL, Lugo JN, Vanegas
F, Turcios E, Mukhi S, Parghi D, D'Arcangelo G and Anderson AE:
Inhibition of the mammalian target of rapamycin blocks epilepsy
progression in NS-Pten conditional knockout mice. Epilepsia.
52:2065–2075. 2011.PubMed/NCBI
|
|
192
|
Gericke B, Brandt C, Theilmann W, Welzel
L, Schidlitzki A, Twele F, Kaczmarek E, Anjum M, Hillmann P and
Löscher W: Selective inhibition of mTORC1/2 or PI3K/mTORC1/2
signaling does not prevent or modify epilepsy in the
intrahippocampal kainate mouse model. Neuropharmacology.
162:1078172020.
|
|
193
|
Buckmaster PS and Lew FH: Rapamycin
suppresses mossy fiber sprouting but not seizure frequency in a
mouse model of temporal lobe epilepsy. J Neurosci. 31:2337–2347.
2011.PubMed/NCBI
|
|
194
|
Overwater IE, Rietman AB, van Eeghen AM
and de Wit MCY: Everolimus for the treatment of refractory seizures
associated with tuberous sclerosis complex (TSC): Current
perspectives. Ther Clin Risk Manag. 15:951–955. 2019.PubMed/NCBI
|
|
195
|
Franz DN, Lawson JA, Yapici Z, Ikeda H,
Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Voi M, et
al: Everolimus for treatment-refractory seizures in TSC: Extension
of a randomized controlled trial. Neurol Clin Pract. 8:412–420.
2018.PubMed/NCBI
|
|
196
|
Ravizza T, Scheper M, Di Sapia R, Gorter
J, Aronica E and Vezzani A: mTOR and neuroinflammation in epilepsy:
Implications for disease progression and treatment. Nat Rev
Neurosci. 25:334–350. 2024.PubMed/NCBI
|
|
197
|
Mazumder AG, Patial V and Singh D:
Mycophenolate mofetil contributes to downregulation of the
hippocampal interleukin type 2 and 1β mediated PI3K/AKT/mTOR
pathway hyperactivation and attenuates neurobehavioral
comorbidities in a rat model of temporal lobe epilepsy. Brain Behav
Immun. 75:84–93. 2019.
|
|
198
|
Drion CM, Borm LE, Kooijman L, Aronica E,
Wadman WJ, Hartog AF, van Vliet EA and Gorter JA: Effects of
rapamycin and curcumin treatment on the development of epilepsy
after electrically induced status epilepticus in rats. Epilepsia.
57:688–697. 2016.PubMed/NCBI
|
|
199
|
Brandt C, Hillmann P, Noack A, Römermann
K, Öhler LA, Rageot D, Beaufils F, Melone A, Sele AM, Wymann MP, et
al: The novel, catalytic mTORC1/2 inhibitor PQR620 and the
PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain
barrier and increase seizure threshold in a mouse model of chronic
epilepsy. Neuropharmacology. 140:107–120. 2018.PubMed/NCBI
|
|
200
|
Castro OW, Upadhya D, Kodali M and Shetty
AK: Resveratrol for easing status epilepticus induced brain injury,
inflammation, epileptogenesis, and cognitive and memory
Dysfunction-Are We There Yet? Front Neurol. 8:6032017.PubMed/NCBI
|
|
201
|
Theilmann W, Gericke B, Schidlitzki A,
Muneeb Anjum SM, Borsdorf S, Harries T, Roberds SL, Aguiar DJ,
Brunner D, Leiser SC, et al: Novel brain permeant mTORC1/2
inhibitors are as efficacious as rapamycin or everolimus in mouse
models of acquired partial epilepsy and tuberous sclerosis complex.
Neuropharmacology. 180:1082972020. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Wang Y and Chen Z: An update for epilepsy
research and antiepileptic drug development: Toward precise circuit
therapy. Pharmacol Ther. 201:77–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Davis KL, Candrilli SD and Edin HM:
Prevalence and cost of nonadherence with antiepileptic drugs in an
adult managed care population. Epilepsia. 49:446–454. 2008.
View Article : Google Scholar
|
|
204
|
Klein P, Kaminski RM, Koepp M and Löscher
W: New epilepsy therapies in development. Nat Rev Drug Discov.
23:682–708. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Forcelli PA: Seizing control of neuronal
activity: Chemogenetic applications in epilepsy. Epilepsy Curr.
22:303–308. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Hadjiabadi D, Lovett-Barron M, Raikov IG,
Sparks FT, Liao Z, Baraban SC, Leskovec J, Losonczy A, Deisseroth K
and Soltesz I: Maximally selective single cell target for circuit
control in epilepsy models. Neuron. 109:2556–2572.e6. 2021.
View Article : Google Scholar :
|
|
207
|
Löscher W: Drug Combinations for
Antiepileptogenesis. Jasper's Basic Mechanisms Epilepsies.
1402–1418. 2024.
|
|
208
|
Szklarczyk D, Santos A, Von Mering C,
Jensen LJ, Bork P and Kuhn M: STITCH 5: Augmenting Protein-chemical
interaction networks with tissue and affinity data. Nucleic Acids
Res. 44:D380–D384. 2016. View Article : Google Scholar
|
|
209
|
Welzel L, Bergin DH, Schidlitzki A, Twele
F, Johne M, Klein P and Löscher W: Systematic evaluation of
rationally chosen multitargeted drug combinations: A combination of
low doses of levetiracetam, atorvastatin and ceftriaxone exerts
antiepileptogenic effects in a mouse model of acquired epilepsy.
Neurobiol Dis. 149:1052272021. View Article : Google Scholar
|
|
210
|
Schidlitzki A, Bascuñana P, Srivastava PK,
Welzel L, Twele F, Töllner K, Käufer C, Gericke B, Feleke R, Meier
M, et al: Proof-of-concept that network pharmacology is effective
to modify development of acquired temporal lobe epilepsy. Neurobiol
Dis. 134:1046642020. View Article : Google Scholar
|
|
211
|
Galanopoulou AS, Löscher W, Lubbers L,
O'Brien TJ, Staley K, Vezzani A, D'Ambrosio R, White HS, Sontheimer
H, Wolf JA, et al: Antiepileptogenesis and disease modification:
Progress, challenges, and the path forward-Report of the
Preclinical Working Group of the 2018 NINDS-sponsored
antiepileptogenesis and disease modification workshop. Epilepsia
Open. 6:276–296. 2021.PubMed/NCBI
|
|
212
|
Porter RJ and Kupferberg HJ: The
anticonvulsant screening program of the National institute of
neurological disorders and stroke, NIH: History and contributions
to clinical care in the twentieth century and beyond. Neurochem
Res. 42:1889–1893. 2017.PubMed/NCBI
|
|
213
|
Kehne JH, Klein BD, Raeissi S and Sharma
S: The national institute of neurological disorders and stroke
(NINDS) epilepsy therapy screening program (ETSP). Neurochem Res.
42:1894–1903. 2017.PubMed/NCBI
|
